JP2018501781A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501781A5 JP2018501781A5 JP2017525950A JP2017525950A JP2018501781A5 JP 2018501781 A5 JP2018501781 A5 JP 2018501781A5 JP 2017525950 A JP2017525950 A JP 2017525950A JP 2017525950 A JP2017525950 A JP 2017525950A JP 2018501781 A5 JP2018501781 A5 JP 2018501781A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- amino acid
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 52
- 239000000611 antibody drug conjugate Substances 0.000 claims description 48
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 35
- 102000036639 antigens Human genes 0.000 claims description 35
- 108091007433 antigens Proteins 0.000 claims description 35
- 239000012634 fragment Substances 0.000 claims description 32
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 239000003112 inhibitor Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 7
- -1 2,5-dioxopyrrolidin-1-yl Chemical group 0.000 claims description 7
- 108050007957 Cadherin Proteins 0.000 claims description 7
- 102000000905 Cadherin Human genes 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- VRDGQQTWSGDXCU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-iodoacetate Chemical compound ICC(=O)ON1C(=O)CCC1=O VRDGQQTWSGDXCU-UHFFFAOYSA-N 0.000 claims description 4
- BQWBEDSJTMWJAE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[(2-iodoacetyl)amino]benzoate Chemical compound C1=CC(NC(=O)CI)=CC=C1C(=O)ON1C(=O)CCC1=O BQWBEDSJTMWJAE-UHFFFAOYSA-N 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010014733 Endometrial cancer Diseases 0.000 claims description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 101710181812 Methionine aminopeptidase Proteins 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 229940125644 antibody drug Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 4
- 239000000032 diagnostic agent Substances 0.000 claims description 4
- 229940039227 diagnostic agent Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 4
- 229940068977 polysorbate 20 Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 3
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000003187 abdominal effect Effects 0.000 claims description 3
- 210000003169 central nervous system Anatomy 0.000 claims description 3
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
- 201000002314 small intestine cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 206010046885 vaginal cancer Diseases 0.000 claims description 3
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 3
- NFJWAGOKMMRHHY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[2-[[2-[[2-[4-(2,5-dioxopyrrol-1-yl)butanoylamino]acetyl]amino]acetyl]amino]acetyl]amino]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCNC(=O)CNC(=O)CNC(=O)CNC(=O)CCCN1C(=O)C=CC1=O NFJWAGOKMMRHHY-UHFFFAOYSA-N 0.000 claims description 2
- NNPUPCNWEHWRPW-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)-2-sulfobutanoic acid Chemical compound OC(=O)C(S(O)(=O)=O)CCSSC1=CC=CC=N1 NNPUPCNWEHWRPW-UHFFFAOYSA-N 0.000 claims description 2
- 229940121819 ATPase inhibitor Drugs 0.000 claims description 2
- 101100004408 Arabidopsis thaliana BIG gene Proteins 0.000 claims description 2
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 2
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 2
- 239000012624 DNA alkylating agent Substances 0.000 claims description 2
- 239000012623 DNA damaging agent Substances 0.000 claims description 2
- 239000012625 DNA intercalator Substances 0.000 claims description 2
- 239000012626 DNA minor groove binder Substances 0.000 claims description 2
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 2
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 2
- 101100485279 Drosophila melanogaster emb gene Proteins 0.000 claims description 2
- 102100029095 Exportin-1 Human genes 0.000 claims description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 2
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 102100027670 Islet amyloid polypeptide Human genes 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 102000029749 Microtubule Human genes 0.000 claims description 2
- 108091022875 Microtubule Proteins 0.000 claims description 2
- 229940119336 Microtubule stabilizer Drugs 0.000 claims description 2
- 229940079156 Proteasome inhibitor Drugs 0.000 claims description 2
- 229940123573 Protein synthesis inhibitor Drugs 0.000 claims description 2
- 101100485284 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CRM1 gene Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 101150094313 XPO1 gene Proteins 0.000 claims description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 2
- 108010044540 auristatin Proteins 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims description 2
- 229930188854 dolastatin Natural products 0.000 claims description 2
- 108700002148 exportin 1 Proteins 0.000 claims description 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims description 2
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 2
- 239000012216 imaging agent Substances 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims description 2
- 229910021645 metal ion Inorganic materials 0.000 claims description 2
- 210000004688 microtubule Anatomy 0.000 claims description 2
- 210000003470 mitochondria Anatomy 0.000 claims description 2
- 230000030147 nuclear export Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 2
- 239000003207 proteasome inhibitor Substances 0.000 claims description 2
- 239000000007 protein synthesis inhibitor Substances 0.000 claims description 2
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 238000006276 transfer reaction Methods 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000010638 Kinesin Human genes 0.000 claims 1
- 108010063296 Kinesin Proteins 0.000 claims 1
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000562 conjugate Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010047741 Vulval cancer Diseases 0.000 description 2
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 201000005102 vulva cancer Diseases 0.000 description 2
- FUHCFUVCWLZEDQ-UHFFFAOYSA-N 1-(2,5-dioxopyrrolidin-1-yl)oxy-1-oxo-4-(pyridin-2-yldisulfanyl)butane-2-sulfonic acid Chemical compound O=C1CCC(=O)N1OC(=O)C(S(=O)(=O)O)CCSSC1=CC=CC=N1 FUHCFUVCWLZEDQ-UHFFFAOYSA-N 0.000 description 1
- 102000000578 Cyclin-Dependent Kinase Inhibitor p21 Human genes 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 229940124179 Kinesin inhibitor Drugs 0.000 description 1
- 201000002454 adrenal cortex cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 208000025854 malignant tumor of adrenal cortex Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462079942P | 2014-11-14 | 2014-11-14 | |
| US62/079,942 | 2014-11-14 | ||
| PCT/IB2015/058801 WO2016075670A1 (en) | 2014-11-14 | 2015-11-13 | Antibody drug conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501781A JP2018501781A (ja) | 2018-01-25 |
| JP2018501781A5 true JP2018501781A5 (OSRAM) | 2018-12-27 |
| JP6831783B2 JP6831783B2 (ja) | 2021-02-17 |
Family
ID=54695810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017525950A Active JP6831783B2 (ja) | 2014-11-14 | 2015-11-13 | 抗体薬物コンジュゲート |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10005836B2 (OSRAM) |
| EP (1) | EP3218410B1 (OSRAM) |
| JP (1) | JP6831783B2 (OSRAM) |
| KR (1) | KR20170084202A (OSRAM) |
| CN (1) | CN108064244B (OSRAM) |
| AR (1) | AR102649A1 (OSRAM) |
| AU (1) | AU2015347015B2 (OSRAM) |
| BR (1) | BR112017009813A2 (OSRAM) |
| CA (1) | CA2967188A1 (OSRAM) |
| CL (1) | CL2017001217A1 (OSRAM) |
| CO (1) | CO2017004782A2 (OSRAM) |
| CR (1) | CR20170200A (OSRAM) |
| EA (1) | EA201791050A1 (OSRAM) |
| EC (1) | ECSP17034845A (OSRAM) |
| ES (1) | ES2987508T3 (OSRAM) |
| GT (1) | GT201700102A (OSRAM) |
| IL (1) | IL252015A0 (OSRAM) |
| MA (1) | MA40913A (OSRAM) |
| MX (1) | MX2017006301A (OSRAM) |
| PE (1) | PE20170912A1 (OSRAM) |
| PH (1) | PH12017500890A1 (OSRAM) |
| SG (1) | SG11201703464UA (OSRAM) |
| TN (1) | TN2017000173A1 (OSRAM) |
| TW (1) | TW201625692A (OSRAM) |
| UY (1) | UY36401A (OSRAM) |
| WO (1) | WO2016075670A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201791050A1 (ru) * | 2014-11-14 | 2017-09-29 | Новартис Аг | Конъюгаты антител и лекарственных средств |
| WO2016203432A1 (en) * | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| EP3468616A1 (en) * | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
| JP7104274B2 (ja) * | 2016-08-19 | 2022-07-21 | Ｐｄｒファーマ株式会社 | 緩衝剤を含む組成物 |
| KR102480247B1 (ko) * | 2016-08-25 | 2022-12-21 | 에프. 호프만-라 로슈 아게 | 다관능화된 규소 나노 입자, 이들의 제조 방법 및 전기 화학 발광 기반 검출 방법에서의 이의 용도 |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| IL303806B2 (en) | 2016-12-22 | 2024-05-01 | Cue Biopharma Inc | Multimeric polypeptides modulate T cells and methods for their use |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
| WO2019197610A1 (en) * | 2018-04-13 | 2019-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New vaccinal strategy |
| EP3802611A2 (en) | 2018-06-01 | 2021-04-14 | Novartis AG | Binding molecules against bcma and uses thereof |
| TW202100184A (zh) * | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體－藥物結合物及使用方法 |
| CA3144324A1 (en) * | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
| JP2022544543A (ja) * | 2019-08-15 | 2022-10-19 | シルバーバック セラピューティックス インコーポレイテッド | ベンザゼピンコンジュゲートの製剤およびその使用 |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| TW202216211A (zh) | 2020-07-01 | 2022-05-01 | 美商希沃爾拜克治療公司 | 抗asgr1抗體共軛物及其用途 |
| TWI771198B (zh) * | 2020-10-20 | 2022-07-11 | 中央研究院 | 用於檢測生物樣本的檢測方法及檢測系統 |
| KR20230119179A (ko) * | 2020-12-10 | 2023-08-16 | 우시 바이올로직스 아일랜드 리미티드 | P-캐드히린에 대한 항체 및 이의 용도 |
| CN117295770A (zh) * | 2021-05-13 | 2023-12-26 | 上海药明生物技术有限公司 | 包含抗p-钙粘蛋白抗体的抗体缀合物及其用途 |
| CN116970083B (zh) * | 2022-04-22 | 2025-04-11 | 上海优卡迪生物医药科技有限公司 | 结合Trop2的抗体或Trop2抗原结合片段以及抗Trop2CAR和应用 |
| WO2024013315A1 (en) * | 2022-07-15 | 2024-01-18 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| WO2025109003A1 (en) | 2023-11-21 | 2025-05-30 | 3B Pharmaceuticals Gmbh | P-cadherin ligands |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (110)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
| US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2071867A1 (en) | 1989-11-06 | 1991-05-07 | Edith Mathiowitz | Method for producing protein microspheres |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| DE69231123T2 (de) | 1992-03-25 | 2001-02-15 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
| AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
| GB9323884D0 (en) | 1993-11-19 | 1994-01-05 | Eisai London Res Lab Ltd | Physiological modulation |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| AU4755696A (en) | 1995-01-05 | 1996-07-24 | Board Of Regents Acting For And On Behalf Of The University Of Michigan, The | Surface-modified nanoparticles and method of making and using same |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP2000507912A (ja) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス，インコーポレイテッド | 作用剤の徐放性組成物 |
| US6169071B1 (en) | 1996-07-12 | 2001-01-02 | Mcgill University | Compounds and methods for modulating cell adhesion |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PT2180007E (pt) | 1998-04-20 | 2013-11-25 | Roche Glycart Ag | Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos |
| IL124650A0 (en) | 1998-05-26 | 1998-12-06 | Yeda Res & Dev | Methods and therapeutic compositions for treating cancer |
| EP1143957A3 (en) | 1998-12-16 | 2002-02-27 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
| ES2327382T3 (es) | 1999-07-20 | 2009-10-29 | Morphosys Ag | Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro. |
| PT1242401E (pt) | 1999-11-24 | 2007-03-30 | Immunogen Inc | Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico |
| PT1242438E (pt) | 1999-12-29 | 2007-02-28 | Immunogen Inc | Agentes citotóxicos compreendendo dixorrubicinas e daunorrubicinas modificadas e seu uso terapêutico |
| US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
| AU2002222939A1 (en) | 2000-07-19 | 2002-01-30 | Takara Bio Inc. | Method of detecting cancer |
| NZ524120A (en) | 2000-07-19 | 2005-08-26 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| AU2001277172A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| CA2445611A1 (en) | 2001-05-31 | 2002-12-05 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| ES2326964T3 (es) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | Composiciones de glicoproteina. |
| WO2003064383A2 (en) | 2002-02-01 | 2003-08-07 | Ariad Gene Therapeutics, Inc. | Phosphorus-containing compounds & uses thereof |
| CA2478065C (en) | 2002-03-08 | 2013-01-08 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| AU2003304203A1 (en) | 2002-10-29 | 2005-01-04 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
| WO2004044000A2 (en) | 2002-11-14 | 2004-05-27 | Adherex Technologies, Inc. | Compounds and methods for modulating functions of classical cadherins |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US20040137538A1 (en) | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive assay kit for identifying cancer protein patterns |
| US20040137539A1 (en) | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies |
| WO2004086038A2 (en) | 2003-03-28 | 2004-10-07 | Institut Curie | A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US20050002919A1 (en) | 2003-06-09 | 2005-01-06 | The Brigham And Women's Hospital, Inc. | Cadherin directed molecular and cellular localization |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| US20050221398A1 (en) | 2004-01-16 | 2005-10-06 | Ipsogen, Sas, A Corporation Of France | Protein expression profiling and breast cancer prognosis |
| EP1735442A2 (en) | 2004-03-24 | 2006-12-27 | Oncotherapy Science, Inc. | Compositions and methods for treating pancreatic cancer |
| US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| CA2597407C (en) | 2005-02-11 | 2013-09-10 | Immunogen, Inc. | Process for preparing stable drug conjugates |
| KR101203328B1 (ko) | 2005-04-26 | 2012-11-20 | 화이자 인코포레이티드 | Ｐ-카드헤린 항체 |
| JP2008540340A (ja) | 2005-04-28 | 2008-11-20 | マクギル ユニバーシティー | カドヘリン介在過程を調節する化合物及び方法 |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| ES2481402T3 (es) | 2005-07-21 | 2014-07-30 | Ardea Biosciences, Inc. | Inhibidores de N-(arilamino)sulfonamida de MEK |
| CA2621502A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| WO2007075672A2 (en) | 2005-12-23 | 2007-07-05 | Lankenau Institute For Medical Research | Prognostic cancer markers |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| JP2009528257A (ja) | 2006-02-28 | 2009-08-06 | オンコセラピー・サイエンス株式会社 | 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法 |
| RS54163B1 (sr) | 2006-05-30 | 2015-12-31 | Genentech Inc. | Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba |
| US20080026481A1 (en) | 2006-06-16 | 2008-01-31 | Michael Mitas | Molecular based two-marker assays that predict outcome of adenocarcinoma patients |
| WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| MX2010008786A (es) | 2008-02-11 | 2010-12-01 | Curetech Ltd | Anticuerpos monoclonales para tratamiento de tumores. |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101764927B1 (ko) | 2008-04-30 | 2017-08-03 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| EP2313504B1 (en) | 2008-06-30 | 2015-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| DK2356270T3 (da) | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| US8455249B2 (en) | 2009-05-01 | 2013-06-04 | The University Of Tokyo | Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| DK2519542T3 (en) | 2009-12-28 | 2019-01-14 | Onco Therapy Science Inc | ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF. |
| PT2535358T (pt) | 2010-02-10 | 2018-02-23 | Perseus Proteomics Inc | Anticorpo anti-caderina marcado com metal radioativo |
| JP2014015396A (ja) | 2010-10-29 | 2014-01-30 | Perseus Proteomics Inc | 高い親和性を有する抗ｃｄｈ３抗体 |
| EP3708586A1 (en) * | 2010-10-29 | 2020-09-16 | Perseus Proteomics Inc. | Anti-cdh3 antibody having high internalization capacity |
| CA2830972C (en) | 2011-04-19 | 2018-11-20 | Pfizer Inc. | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| JPWO2012176765A1 (ja) | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体 |
| HK1206386A1 (en) * | 2012-04-04 | 2016-01-08 | Perseus Proteomics Inc. | Conjugate of anti-cdh3 (p-cadherin) antibody and drug |
| WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
| WO2014126198A1 (ja) * | 2013-02-15 | 2014-08-21 | 株式会社ペルセウスプロテオミクス | 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 |
| EA201791050A1 (ru) * | 2014-11-14 | 2017-09-29 | Новартис Аг | Конъюгаты антител и лекарственных средств |
| WO2016203432A1 (en) * | 2015-06-17 | 2016-12-22 | Novartis Ag | Antibody drug conjugates |
| US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2015
- 2015-11-13 EA EA201791050A patent/EA201791050A1/ru unknown
- 2015-11-13 UY UY0001036401A patent/UY36401A/es not_active Application Discontinuation
- 2015-11-13 MX MX2017006301A patent/MX2017006301A/es unknown
- 2015-11-13 ES ES15798251T patent/ES2987508T3/es active Active
- 2015-11-13 CN CN201580071419.9A patent/CN108064244B/zh active Active
- 2015-11-13 CA CA2967188A patent/CA2967188A1/en not_active Abandoned
- 2015-11-13 SG SG11201703464UA patent/SG11201703464UA/en unknown
- 2015-11-13 CR CR20170200A patent/CR20170200A/es unknown
- 2015-11-13 US US14/940,961 patent/US10005836B2/en active Active
- 2015-11-13 TN TN2017000173A patent/TN2017000173A1/en unknown
- 2015-11-13 JP JP2017525950A patent/JP6831783B2/ja active Active
- 2015-11-13 TW TW104137588A patent/TW201625692A/zh unknown
- 2015-11-13 AR ARP150103709A patent/AR102649A1/es unknown
- 2015-11-13 BR BR112017009813A patent/BR112017009813A2/pt not_active Application Discontinuation
- 2015-11-13 WO PCT/IB2015/058801 patent/WO2016075670A1/en not_active Ceased
- 2015-11-13 MA MA040913A patent/MA40913A/fr unknown
- 2015-11-13 PE PE2017000847A patent/PE20170912A1/es unknown
- 2015-11-13 EP EP15798251.3A patent/EP3218410B1/en active Active
- 2015-11-13 KR KR1020177015786A patent/KR20170084202A/ko not_active Withdrawn
- 2015-11-13 AU AU2015347015A patent/AU2015347015B2/en not_active Ceased
-
2017
- 2017-04-30 IL IL252015A patent/IL252015A0/en unknown
- 2017-05-12 CL CL2017001217A patent/CL2017001217A1/es unknown
- 2017-05-12 PH PH12017500890A patent/PH12017500890A1/en unknown
- 2017-05-12 CO CONC2017/0004782A patent/CO2017004782A2/es unknown
- 2017-05-12 GT GT201700102A patent/GT201700102A/es unknown
- 2017-06-05 EC ECIEPI201734845A patent/ECSP17034845A/es unknown
-
2018
- 2018-05-24 US US15/988,659 patent/US10626172B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018501781A5 (OSRAM) | ||
| JP2016518332A5 (OSRAM) | ||
| JP2016512832A5 (OSRAM) | ||
| US20210301031A1 (en) | Napi2b-targeted antibody-drug conjugates and methods of use thereof | |
| TWI804499B (zh) | Ror1抗體免疫接合物 | |
| SI2582728T1 (en) | Human Antibodies Conjugates against a Tissue Factor | |
| JP2022101693A5 (OSRAM) | ||
| JP2020502271A5 (OSRAM) | ||
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| RU2017102988A (ru) | Антитела против рецептора фолиевой кислоты 1, их иммуноконъюгаты и использование | |
| JP2019500020A5 (OSRAM) | ||
| JP2010518115A5 (OSRAM) | ||
| HRP20200283T1 (hr) | Protutijela koja se vežu na axl | |
| JP2016503295A5 (OSRAM) | ||
| TW201834697A (zh) | Her2標靶抗體－藥物結合物之組合療法 | |
| IL278574B1 (en) | Compounds acting on glycans and methods of using them | |
| JP2020526584A5 (OSRAM) | ||
| JP2020500834A5 (OSRAM) | ||
| JP2025061007A5 (OSRAM) | ||
| CN119317447A (zh) | 抗可变muc1*抗体及其用途 | |
| WO2024145398A1 (en) | Antibody drug conjugates | |
| IL317410A (en) | Cancer treatment with PD-1 or PD-L1 inhibitor and antibody-drug conjugates targeting claudin 18.2 | |
| WO2025213130A1 (en) | Antibody drug conjugates | |
| TW202542193A (zh) | 抗原結合分子、其藥物偶聯物及其醫藥用途 | |
| AU2023346641A1 (en) | Humanized antibodies against nectin-4 and drug conjugates thereof |